Melanoma and Non-Small Cell Lung Cancer
Clinical research is centred on melanoma and non-small cell lung cancer in patients whose disease no longer responds to anti-PD-1 and anti-PD-L1 therapy.
- Checkpoint inhibitor resistance
- Immune checkpoint blockade
- Tumour immune response
The therapeutic interest lies in immuno-oncology for refractory solid tumours, with emphasis on restoring antitumour activity in treatment-resistant disease.
Nivolumab and Ipilimumab
Research activity includes combination strategies built around nivolumab and ipilimumab, both central to immune checkpoint modulation in advanced cancer.
- PD-1 pathway inhibition
- CTLA-4 targeting
- Combination immunotherapy
This area reflects a focus on dual-pathway immune activation in melanoma and lung cancer settings with prior exposure to checkpoint therapy.
Epigenetic Therapy
The sponsor also supports investigation of oral decitabine and cedazuridine within an epigenetic treatment context for resistant tumours.
- DNA methylation modulation
- Hypomethylating agents
- Immune sensitisation
Interest in this domain is linked to modifying the tumour environment to improve responsiveness in immunotherapy-refractory disease.
